Steven Leonard Chapman Sells 9,109 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 9,109 shares of the business’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $1,476,113.45. Following the completion of the sale, the chief executive officer owned 168,155 shares of the company’s stock, valued at $27,249,517.75. The trade was a 5.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The shares were sold at an average price of $166.53, for a total value of $845,805.87.
• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The stock was sold at an average price of $132.88, for a total value of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The stock was sold at an average price of $139.81, for a total value of $851,722.52.
• On Monday, July 21st, Steven Leonard Chapman sold 1,622 shares of Natera stock. The stock was sold at an average price of $139.29, for a total value of $225,928.38.

Natera Stock Down 0.9%

Natera stock opened at $160.21 on Friday. The business has a fifty day moving average of $160.60 and a two-hundred day moving average of $156.43. The firm has a market cap of $21.99 billion, a P/E ratio of -83.88 and a beta of 1.74. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm’s quarterly revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Natera by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after acquiring an additional 282,826 shares during the period. JPMorgan Chase & Co. increased its position in shares of Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares during the period. Geode Capital Management LLC increased its position in shares of Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock valued at $430,640,000 after acquiring an additional 166,768 shares during the period. Finally, Invesco Ltd. increased its position in shares of Natera by 13.7% in the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock valued at $287,908,000 after acquiring an additional 245,719 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 target price for the company in a report on Monday, July 28th. Wells Fargo & Company started coverage on Natera in a report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price objective for the company. Stephens reiterated an “overweight” rating and set a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Finally, Barclays reiterated an “overweight” rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $192.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.